Document Detail


Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.
MedLine Citation:
PMID:  22284242     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Incretin-based therapies, which include the GLP-1 receptor agonists and DPP-4 inhibitors, use the antidiabetic properties of potentiating the GLP-1 receptor signalling via the regulation of insulin and glucagon secretion, inhibition of gastric emptying and suppression of appetite. Most physicians will start antidiabetic treatment with metformin, but adding a GLP-1 receptor agonist as the second drug seems to be optimal since more patients will reach an HbA1c below 7% than with a DPP-4 inhibitor or another oral antidiabetic agents and with minimal risk of hypoglycaemia. The GLP-1 receptor agonists are also more effective in weight and systolic blood pressure control than DPP-4 inhibitors. The side effects of the GLP-1 receptor agonists are primarily nausea and vomiting, which is less pronounced with the long acting agonists and often transient. A GLP-1 receptor agonist can be recommended before a DPP-4 inhibitor in obese type 2 diabetic patients, who want to lose weight. Furthermore, the GLP-1 receptor agonists cover the whole spectrum of treatment from time of diagnosis with lifestyle treatment to combination treatment with basal insulin.
Authors:
Sten Madsbad
Publication Detail:
Type:  Comment; Journal Article     Date:  2011-11-29
Journal Detail:
Title:  European journal of internal medicine     Volume:  23     ISSN:  1879-0828     ISO Abbreviation:  Eur. J. Intern. Med.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-01-30     Completed Date:  2012-06-26     Revised Date:  2013-03-19    
Medline Journal Info:
Nlm Unique ID:  9003220     Medline TA:  Eur J Intern Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  132-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Affiliation:
Department of Endocrinology, Hvidovre University Hospital, 2650 Hvidovre, Denmark. sten.madsbad@hvh.regionh.dk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose / metabolism*
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Humans
Receptors, Glucagon / agonists*
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Dipeptidyl-Peptidase IV Inhibitors; 0/Receptors, Glucagon; 0/glucagon-like peptide-1 receptor
Comments/Corrections
Comment On:
Eur J Intern Med. 2012 Mar;23(2):126-31   [PMID:  22284241 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor ...
Next Document:  The association of physical activity with novel adipokines in patients with type 2 diabetes.